(English)

From China, Bridging Biopharmaceutical Innovation in Korea

Chime Biologics Empowers a New Landscape for Korea's Biopharma Industry

Recently, the 2026 Hubei–Korea Future Cooperation Exchange Event was successfully held in Wuhan, China. As an important platform for efficient collaboration between Chinese and Korean industries and capital, the event brought together government agencies, financial institutions, well-known enterprises, and industry representatives from both countries to conduct in-depth exchanges on strategic emerging industries, with a focus on biomedicine.

During a panel discussion, Ms. Zhao Dandan, Director of Operation at Chime Biologics, shared insights and practical experiences on the synergistic development of the biopharmaceutical industries in China and Korea, highlighting Chime Biologics' unique value in the global biopharma supply chain.

Korea's Biopharma Industry: From Rise to Upgrading

Over the past decade, Korea has achieved rapid development in the field of large-molecule biologics.

By initially leveraging the transfer of pharmaceutical manufacturing from Europe and the United States, Korea has transformed biologics CMC development and commercial production into a key high-tech national industry, giving rise to several large-scale CDMOs with global competitiveness.

However, beneath this successful trajectory, structural challenges have gradually emerged:

  • The scale-driven CMO/CDMO model primarily serves large global pharmaceutical companies
  • The high-investment, high-return business model concentrates resources on late-stage and commercial development
  • The early-stage development needs of local innovative biopharma companies remain underserved
The Rise of Chinese Capabilities: Reshaping Industrial Supply Side Capacity

With the rapid development of China's biopharmaceutical industry, the industry landscape is undergoing profound changes.

In the CDMO and upstream supply chain sectors, China has already produced a number of globally competitive enterprises. Following several years of rapid growth and consolidation, leading players have begun to take shape, presenting new industrial capability characteristics:

  • End-to-end capabilities covering everything from early development to commercial production
  • Execution systems that combine efficiency and cost advantages
  • Development pathways that support both innovative drugs and biosimilars

This capability set precisely fills critical gaps in the Korean biopharma industry at different stages of its development.

Chime Biologics: A Key Bridge Connecting Innovation in China and Korea

Within this industrial evolution, Chime Biologics is gradually becoming an important partner for Korean biopharma companies.

Leveraging its international technology systems and efficient execution capabilities, Chime Biologics offers multi-tiered value to its Korean clients:

  • Empowering Early-Stage Innovation Development: Supporting Korean local innovative biopharma companies in achieving more efficient and cost-effective CMC development in the early R&D phase, accelerating project progress
  • Supporting Scalable Competition for Biosimilars: Providing efficient and competitively priced commercial production solutions for new players entering the biosimilar market
  • Building Long-Term Strategic Partnerships: Empowering Korean innovative biologics and biosimilars to reach global markets – particularly emerging markets such as ASEAN, the Middle East, and North Africa, which become accessible as affordability barriers are lowered, driven by the highly efficient supply chain of China's biologics manufacturing

Looking ahead, Chime Biologics will continue to deepen collaboration with partners in Korea and around the world, helping to bring more innovative therapies to market faster and benefit patients globally.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.

For more information, please visit www.chimebiologics.com.